Seres Therapeutics, Inc.
MCRBSeres Therapeutics, Inc. in brief
Seres Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2010. Its market value was $20 M on 30 October 2026, which makes it the 24,364th largest listed company in the world and the 4,161st largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net profit of $6 M. It employs about 333 people and Eric Shaff is its chief executive. Its shares trade under the symbol MCRB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Seres Therapeutics, Inc.
Seres Therapeutics is a Late Clinical Stage Biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company annual revenue is 35 million USD and 145 employees as on 2020. The headquarters is in USA.
Seres Therapeutics, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- ✎Renamed Seres Therapeutics, Inc.Formerly Seres Health, Inc..
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 26 June 2015; shares registered for exchange trading on 22 June 2015.
- 2021
- 💰Record revenue of $145 millionFY2021, the highest of the 6 years on record.
Events of Seres Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,131 (Jan 2020) · #1,573 (Jan 2021) · #2,780 (Jan 2022) · #2,367 (Dec 2022) · #2,526 (Jul 2023) · #3,326 (Jan 2024) · #1,995 (Mar 2026) · #3,767 (Aug 2026) · #4,164 (Oct 2026)
Key ratios
- P/E ratio
- 3.5×
- Price / sales
- 25.2×
- Price / book
- 0.4×
- Free cash flow yield
- 4.4%
- Net margin
- 721.5%
- Operating margin
- -11894.9%
- Return on equity
- 12.9%
- Liabilities / assets
- 68.0%
- Net debt
- $-18M
- Revenue growth
- -88.9%
- R&D / revenue
- 6210.1%
- Revenue per employee
- $2 K
- Profit per employee
- $17 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | — | $-94M | $6M | 721.5% |
| Dec 2024 | — | — | $-121M | $0M | — |
| Dec 2023 | — | — | $-195M | $-114M | — |
| Dec 2022 | $7M | -95.1% | $-180M | $-250M | -3508.6% |
| Dec 2021 | $145M | +336.3% | $-64M | $-66M | -45.2% |
| Dec 2020 | $33M | -3.7% | $-88M | $-89M | -268.3% |
| Dec 2019 | $35M | +22.0% | $-72M | $-70M | -203.7% |
| Dec 2018 | $28M | — | $-100M | $-99M | -350.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $1M | $0M | $1M | $0.64 | — |
| Dec 2024 | $-149M | $0M | $-149M | $0.00 | — |
| Dec 2023 | $-117M | $8M | $-125M | $-17.77 | — |
| Dec 2022 | $-229M | $10M | $-239M | $-2.31 | — |
| Dec 2021 | $7M | $10M | $-3M | $-0.72 | — |
| Dec 2020 | $-94M | $1M | $-94M | $-1.12 | — |
| Dec 2019 | $-77M | $1M | $-78M | $-1.24 | — |
| Dec 2018 | $-63M | $2M | $-65M | $-2.43 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+68.6% on a year earlier), net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 26, 20268-KCurrent reportDirectors or officers changed
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Aug 4, 20268-KCurrent reportMaterial agreement · Agreement ended
- Jul 8, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jul 8, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 5, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jun 1, 20268-KCurrent reportDirectors or officers changed
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
Official filings of Seres Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-94 M
- Net income
- $6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $138 M
- Total liabilities
- $94 M
- Total equity
- $44 M
As of December-2025
Top 40 institutional investors in Seres Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Flagship Pioneering, LLC | 1,155,850 | 0 (0.00%) | 11.34% | $4 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 286,405 | -1,371 (-0.48%) | 2.81% | $1 M | Nov 13, 2026 |
| 3 | Marshall Wace, LLP | 139,278 | -32,967 (-19.14%) | 1.37% | $0 M | Nov 13, 2026 |
| 4 | Jacobs Levy Equity Management, Inc | 134,375 | New | 1.32% | $0 M | Nov 16, 2026 |
| 5 | Vontobel Holding Ltd. | 114,566 | -8,409 (-6.84%) | 1.12% | $0 M | Oct 16, 2026 |
| 6 | BlackRock, Inc. | 109,827 | -1,173 (-1.06%) | 1.08% | $0 M | Nov 13, 2026 |
| 7 | Geode Capital Management, LLC | 78,898 | -1,076 (-1.35%) | 0.77% | $0 M | Nov 6, 2026 |
| 8 | Susquehanna International Group, LLP | 62,692 | +4,364 (+7.48%) | 0.61% | $0 M | Nov 16, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 48,685 | 0 (0.00%) | 0.48% | $0 M | Nov 13, 2026 |
| 10 | State Street Corp | 33,901 | 0 (0.00%) | 0.33% | $0 M | Nov 12, 2026 |
| 11 | Lion Point Capital, LP | 31,570 | 0 (0.00%) | 0.31% | $0 M | Nov 16, 2026 |
| 12 | Goldman Sachs Group Inc | 17,888 | +2,659 (+17.46%) | 0.18% | $0 M | Nov 16, 2026 |
| 13 | Quadrature Capital Ltd | 17,428 | New | 0.17% | $0 M | Nov 13, 2026 |
| 14 | J. Safra Sarasin Holding AG | 14,997 | New | 0.15% | $0 M | Oct 26, 2026 |
| 15 | Northern Trust Corp | 14,750 | -15 (-0.10%) | 0.14% | $0 M | Nov 16, 2026 |
| 16 | Invesco Ltd. | 12,603 | -371 (-2.86%) | 0.12% | $0 M | Nov 12, 2026 |
| 17 | Morgan Stanley | 12,283 | +145 (+1.19%) | 0.12% | $0 M | Nov 13, 2026 |
| 18 | Renaissance Technologies LLC | 11,791 | New | 0.12% | $0 M | Nov 12, 2026 |
| 19 | Squarepoint Ops LLC | 11,523 | New | 0.11% | $0 M | Nov 9, 2026 |
| 20 | XTX Topco Ltd | 10,705 | -10,027 (-48.36%) | 0.10% | $0 M | Nov 16, 2026 |
| 21 | Group One Trading LLC | 3,714 | 0 (0.00%) | 0.04% | $0 M | Nov 10, 2026 |
| 22 | SBI Securities Co., Ltd. | 3,601 | -581 (-13.89%) | 0.04% | $0 M | Oct 22, 2026 |
| 23 | UBS Group AG | 3,493 | +3,009 (+621.69%) | 0.03% | $0 M | Nov 10, 2026 |
| 24 | Tower Research Capital LLC (TRC) | 2,173 | +1,857 (+587.66%) | 0.02% | $0 M | Nov 16, 2026 |
| 25 | Vanguard Global Advisers, LLC | 1,975 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
Show all 40: investors 26 to 40
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nuveen, LLC | 1,773 | New | 0.02% | $0 M | Nov 10, 2026 |
| 27 | FMR LLC | 1,730 | +202 (+13.22%) | 0.02% | $0 M | Nov 10, 2026 |
| 28 | Rachor Investment Advisory Services, LLC | 1,185 | -292 (-19.77%) | 0.01% | $0 M | Oct 29, 2026 |
| 29 | Jpmorgan Chase & Co | 746 | -2,890 (-79.48%) | 0.01% | $0 M | Nov 12, 2026 |
| 30 | Royal Bank Of Canada | 316 | +305 (+2772.73%) | 0.00% | $0 M | Nov 16, 2026 |
| 31 | Pinnacle Financial Group, Inc. | 300 | — | 0.00% | $0 M | Nov 16, 2026 |
| 32 | BNP Paribas Financial Markets | 214 | +3 (+1.42%) | 0.00% | $0 M | Nov 12, 2026 |
| 33 | Continuum Advisory, LLC | 47 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 34 | PNC Financial Services Group, Inc. | 23 | New | 0.00% | $0 M | Nov 6, 2026 |
| 35 | Simplex Trading, LLC | 18 | -4,580 (-99.61%) | 0.00% | $0 M | Nov 4, 2026 |
| 36 | Wells Fargo & Company/mn | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 37 | Osaic Holdings, Inc. | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 38 | Larson Financial Group LLC | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 39 | Barclays PLC | 4 | -163 (-97.60%) | 0.00% | $0 M | Nov 6, 2026 |
| 40 | Allworth Financial LP | 4 | New | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding Seres Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 206,170 | $2 M | 2.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 75,849 | $1 M | 0.74% | <0.01% | +8.4% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust | 37,364 | $0 M | 0.37% | <0.01% | −33% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 31,077 | $0 M | 0.30% | <0.01% | −1.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 25,389 | $0 M | 0.25% | 0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 26,335 | $0 M | 0.26% | <0.01% | +8.9% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,870 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 10,065 | $0 M | 0.10% | <0.01% | +277% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,143 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 12,914 | $0 M | 0.13% | <0.01% | −11% | Jul 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 7,500 | $0 M | 0.07% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc. | 7,058 | $0 M | 0.07% | <0.01% | −2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,666 | $0 M | 0.06% | <0.01% | +26% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 5,277 | $0 M | 0.05% | <0.01% | −2.9% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 7,662 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,386 | $0 M | 0.04% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,689 | $0 M | 0.02% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 1,430 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 1,371 | $0 M | 0.01% | <0.01% | −91% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust | 1,176 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 1,022 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 42 | $0 M | <0.01% | <0.01% | +17% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Seres Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Matthew R. HennSee Remarks | Sell10b5-1 plan | -101 | $1.380 | $139 | 8,132 | Form 4 |
| filed | Eric D. ShaffDirector | Sell10b5-1 plan | -287 | $1.380 | $396 | 12,936 | Form 4 |
| filed | Thomas DesRosierSee Remarks | Sell10b5-1 plan | -103 | $1.380 | $142 | 8,258 | Form 4 |
| filed | Kelly BradySee Remarks | Sell10b5-1 plan | -85 | $1.380 | $117 | 8,775 | Form 4 |
| filed | Matthew R. HennSee Remarks | Option exercise10b5-1 plan | +238 | — | — | 8,233 | Form 4 |
| filed | Eric D. ShaffDirector | Option exercise10b5-1 plan | +724 | — | — | 13,223 | Form 4 |
| filed | Thomas DesRosierSee Remarks | Option exercise10b5-1 plan | +244 | — | — | 8,361 | Form 4 |
| filed | Kelly BradySee Remarks | Option exercise10b5-1 plan | +181 | — | — | 8,860 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Seres Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 20-for-1 split
Trading halts
- 2026-02-12 11:55 UTC, code T3, resumed 12:30 UTC
- 2025-04-23 13:34 UTC, code LUDP, resumed 13:47 UTC
- 2025-04-21 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 10,229 shares at $1.95
- : 10,000 shares at $1.79
- : 4,704 shares at $1.80
- : 1,460 shares at $2.31
- : 71 shares at $2.42
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Seres Therapeutics, Inc. scorecard#
Passes 8 of the 14 checks that could be worked out: strongest in profitability (2 of 3), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation3 of 5
- ✓P/E below its peers' median3.5×P/E 3.5× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median25.2×Price to sales 25.2× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%4.4%Free cash flow is 4.4% of the market value.
- ✓Earnings yield above the 10-year Treasury yield28.7%Earnings yield 28.7% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year0.64 vs 0.00Diluted EPS 0.64 in fiscal 2025 against 0.00 the year before (report's currency).
- ✓Net income higher than five years earlier$6 M$6 M in fiscal 2025 against -$89 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 3
- ✓Profitable in the newest year$6 MNet income $6 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✓Return on equity above 15%19.7%19.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.56 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-11.70Z-score -11.70 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.2%Diluted shares up 14.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Seres Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.8—100% | 0—— | 0r126−100%— | 7.1−95.1%100% | 145+336%100% | 33−3.7%100% | 35+22.1%100% | 28−11.9%100% | 32+47.5%100% | 22—100% | |
| Research and development | 49−24.1%6218% | 65−45.1%— | 118r146+7.2%— | 110r173−22.7%1538% | 142+56.7%97.9% | 91+13.0%273% | 80−16.5%232% | 96+7.3%339% | 89+9.1%279% | 82—377% | |
| General and administrative | 39−26.4%4963% | 53−31.4%— | 78r88+10.3%— | 70r80+1.4%986% | 69+125%47.8% | 31+24.4%92.7% | 25−24.1%71.7% | 33−4.2%115% | 34+4.4%106% | 33—150% | |
| Operating expenses | 95−21.9%12010% | 121−37.8%— | 195r234+8.4%— | 180r254−14.1%2524% | 209+72.6%145% | 121+14.1%365% | 106−17.2%308% | 129+4.1%455% | 123+7.8%385% | 115—527% | |
| Operating income | −94—−11910% | −121—— | −195r−108—— | −180r−246—−2524% | −64—−44.5% | −88—−265% | −72—−208% | −100—−355% | −91—−285% | −93—−427% | |
| Interest and finance income | 2.2−43.9%282% | 4.0−45.7%— | 7.3+139%— | 3.1+6.6%42.9% | 2.9+203%2.0% | 0.9−8.4%2.8% | 1.0−11.9%3.0% | 1.2−26.3%4.1% | 1.6—5.0% | — | |
| Interest expense and finance costs | 0—0.0% | 0−100%— | 2.5r13−59.0%— | 6.0+107%84.5% | 2.9−0.5%2.0% | 2.9+482%8.8% | 0.5—1.5% | — | — | — | |
| Net interest income | — | — | — | — | — | — | — | — | 1.6+26.2%5.0% | 1.3—5.8% | |
| Other non-operating income (expense) | 100—12632% | −4.5−190%— | 5.0r−5.7—— | −3.7—−51.4% | −1.1—−0.7% | −1.0−162%−3.0% | 1.6+19.0%4.6% | 1.3−33.4%4.7% | 2.0+59.9%6.3% | 1.3—5.8% | |
| Income tax | 0—0.0% | 0—— | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | 5.7—722% | −126—— | −190—— | −184—−2575% | — | — | — | — | — | — | |
| Income from discontinued operations | 0−100%0.0% | 126+64.8%— | 76—— | −67—−934% | — | — | — | — | — | — | |
| Net income attributable to shareholders | 5.7+4088%722% | 0.1—— | −114—— | −250—−3509% | −66—−45.2% | −89—−268% | −70—−204% | −99—−350% | −89—−278% | −92—−421% | |
| Earnings per share, basic | 0.64—— | 0.00—— | -17.77r-0.89—— | -2.31—— | -0.72—— | -1.12—— | -1.24—— | -2.43—— | -2.21—— | -2.30—— | |
| Earnings per share, diluted | 0.64—— | 0.00—— | -17.77r-0.89—— | -2.31—— | -0.72—— | -1.12—— | -1.24—— | -2.43—— | -2.21—— | -2.30—— | |
| Shares, weighted average (basic) | 8.9+14.0%— | 7.8r155+21.4%— | 6.4r128−94.1%— | 108+17.9%— | 92+14.9%— | 80—— | — | — | — | — | |
| Shares, weighted average (diluted) | 8.9+14.2%— | 7.8r155+21.4%— | 6.4r128−94.1%— | 108+17.9%— | 92+14.9%— | 80+40.8%— | 57+39.0%— | 41+0.7%— | 40+1.5%— | 40—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 46+48.6%33.1% | 31−75.9%22.0% | 128−21.5%35.7% | 163−9.4%46.7% | 180+55.1%50.7% | 116+78.2%33.8% | 65−24.1%49.2% | 86+138%71.2% | 36−33.8%19.0% | 55—20.0% | |
| Short-term investments | — | — | 0−100%0.0% | 18−83.5%5.2% | 111−19.5%31.2% | 138+363%40.1% | 30—22.4% | 0−100%0.0% | 114−17.9%60.1% | 139—50.9% | |
| Receivables | 0.2—0.1% | 0—0.0% | — | — | — | 9.4+426%2.7% | 1.8—1.3% | — | — | — | |
| Inventory | — | — | 30—8.3% | 0—0.0% | — | — | — | — | — | — | |
| Other current assets | 3.1−46.8%2.2% | 5.8−27.8%4.2% | 8.0r9.1−40.0%2.2% | 13+3.9%3.8% | 13+124%3.6% | 5.8+60.9%1.7% | 3.6−47.6%2.7% | 6.8+34.3%5.7% | 5.1−0.6%2.7% | 5.1—1.9% | |
| Current assets | 49+27.7%35.7% | 39−78.0%27.7% | 175−9.9%48.9% | 195−35.9%55.8% | 304+13.0%85.6% | 269+168%78.4% | 100+8.1%75.6% | 93−40.2%76.9% | 155−21.8%81.8% | 198—72.8% | |
| Property, plant and equipment | 7.6−33.8%5.5% | 12−34.5%8.2% | 18r22−23.4%4.9% | 23+28.1%6.6% | 18+29.1%5.1% | 14−28.7%4.1% | 19−25.9%14.7% | 26−20.2%21.8% | 33−8.8%17.4% | 36—13.2% | |
| Right-of-use (leased) assets | 72−10.4%52.5% | 81−10.5%57.9% | 90r110−18.5%25.2% | 111+510%31.8% | 18+101%5.1% | 9.0−20.4%2.6% | 11—8.6% | — | — | — | |
| Long-term investments | — | — | — | 0−100%0.0% | 0.5−99.0%0.1% | 50—14.5% | — | — | — | 37—13.5% | |
| Total assets | 138−1.2%100% | 140−61.0%100% | 359+2.8%100% | 349−1.7%100% | 355+3.5%100% | 343+159%100% | 132+9.9%100% | 120−36.4%100% | 190−30.5%100% | 273—100% | |
| Accounts payable | 1.7−58.8%1.2% | 4.1+12.0%2.9% | 3.6−79.1%1.0% | 17+27.0%5.0% | 14+242%3.9% | 4.0−17.3%1.2% | 4.9−24.3%3.7% | 6.4−8.8%5.3% | 7.0−7.3%3.7% | 7.6—2.8% | |
| Current liabilities | 19−53.1%14.0% | 41−58.2%29.5% | 99+15.3%27.5% | 86+4.1%24.5% | 82+77.2%23.2% | 46+0.9%13.5% | 46+9.4%34.7% | 42+32.9%34.9% | 32+3.8%16.7% | 30—11.2% | |
| Lease liabilities (non-current) | 73−12.5%52.5% | 83−9.5%59.3% | 92r106−15.1%25.6% | 108+501%30.9% | 18+70.0%5.1% | 11−32.6%3.1% | 16—11.8% | — | — | — | |
| Total liabilities | 94−25.4%68.0% | 126−68.8%90.1% | 403+19.4%113% | 338+51.3%96.9% | 223+32.8%62.9% | 168−7.0%49.0% | 181+7.3%136% | 169+30.8%140% | 129−8.0%68.0% | 140—51.4% | |
| Retained earnings | −972—−704% | −978—−700% | −978—−273% | −865—−248% | −614—−173% | −549—−160% | −460—−347% | −389—−323% | −264—−139% | −174—−63.9% | |
| Shareholders' equity | 44+221%32.0% | 14—9.9% | −45−516%−12.5% | 11−91.8%3.1% | 132−24.7%37.1% | 175—51.0% | −48—−36.5% | −48−179%−39.9% | 61−54.2%32.0% | 133—48.6% | |
| Total liabilities and equity | 138−1.2%100% | 140−61.0%100% | 359+2.8%100% | 349−1.7%100% | 355+3.5%100% | 343+159%100% | 132+9.9%100% | 120−36.4%100% | 190−30.5%100% | 273—100% | |
| Shares outstanding | 9.6r9.6+10.5%— | 8.7r173−93.6%— | 135+7.8%— | 125+36.3%— | 92+0.5%— | 91+30.4%— | 70+71.3%— | 41+0.9%— | 41+0.5%— | 40—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 4.1−24.4%524% | 5.5−12.4%— | 6.2−5.8%— | 6.6+11.5%93.0% | 5.9−9.6%4.1% | 6.6−13.5%19.8% | 7.6−3.3%22.0% | 7.9+8.3%27.8% | 7.3+72.6%22.6% | 4.2—19.3% | |
| Share-based compensation | 11−48.3%1374% | 21−38.5%— | 34+33.8%— | 25+26.0%357% | 20+129%14.0% | 8.8+5.8%26.6% | 8.3−49.9%24.2% | 17−4.2%58.9% | 17+3.0%54.1% | 17—77.4% | |
| Cash from operating activities | 1.1—142% | −149—— | −117—— | −229−3521%−3210% | 6.7—4.6% | −94—−282% | −77—−222% | −63—−222% | −76−272%−235% | 44—202% | |
| Capital expenditure | −0.3—−31.9% | −0.4—— | −8.0—— | −9.8—−138% | −9.6—−6.6% | −0.6—−1.8% | −1.0—−2.9% | −1.9—−6.9% | −4.7—−14.6% | −21—−98.7% | |
| Cash from investing activities | −0.0−100%−5.3% | 142+1245%— | 11−87.2%— | 82+28.6%1156% | 64—44.2% | −159—−478% | −31−127%−88.4% | 112+102%397% | 56r57—174% | −66r−65—−301% | |
| Debt issued | 0—0.0% | 0−100%— | 103+274%— | 28—387% | 0—0.0% | 0−100%0.0% | 25—72.5% | — | — | — | |
| Shares issued | — | 0—— | 0−100%— | 97—1357% | 0−100%0.0% | 244+303%734% | 61—175% | — | — | — | |
| Shares bought back | — | — | — | — | — | — | — | — | −0.0—−0.1% | — | |
| Cash from financing activities | 14—1761% | −90−226%— | 72−44.7%— | 130+10902%1818% | 1.2−99.6%0.8% | 303+252%914% | 86+32076%250% | 0.3+223%0.9% | 0.1−96.1%0.3% | 2.1—9.8% | |
| Change in cash | — | — | — | — | — | 51—153% | −21−142%−60.3% | 50—176% | −20r−18—−61.5% | −20r−19—−89.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.1+505%100% | 0.6+68.9%100% | 0.7—100% | 0.4—100% | 0.4*—100% | 0.4—100% | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | |
| Research and development | 40−21.1%1864% | 5.6−55.7%943% | 9.1−29.4%1242% | 13+11.6%3686% | 12*−9.0%2668% | 13−23.4%3594% | 13−18.1%— | 12−39.4%— | 13*−44.3%— | 16—— | 16r18—— | 19r22—— | 23r27*—— | |
| General and administrative | 28−36.2%1323% | 5.4−42.5%919% | 7.1−31.1%959% | 8.1−32.1%2254% | 7.5*−39.5%1721% | 9.5−25.4%2700% | 10−21.5%— | 12−20.4%— | 12*−10.9%— | 13—— | 13r16—— | 15r15—— | 14r17*—— | |
| Operating expenses | 80−23.1%3757% | 17−26.6%2824% | 22−11.5%2990% | 21−21.9%5940% | 20*−31.3%4524% | 23−21.7%6504% | 25−13.8%— | 27−20.9%— | 29*−22.1%— | 29—— | 29r31—— | 34r40—— | 37r40*—— | |
| Operating income | −78—−3657% | −16—−2724% | −21—−2890% | −21—−5840% | −19*—−4424% | −22—−6404% | −25—— | −27—— | −29*—— | −29—— | −29r−31—— | −34r−40—— | −37r−40*—— | |
| Interest and finance income | 1.1−50.6%51.6% | 0.1−76.4%24.6% | 0.2−66.8%24.6% | 0.3−47.4%90.8% | 0.4*+1.8%102% | 0.6−5.2%176% | 0.5−55.6%— | 0.6−62.5%— | 0.4*−77.8%— | 0.7—— | 1.2—— | 1.6—— | 2.0*—— | |
| Interest expense and finance costs | — | — | — | — | — | — | 0—— | 0−100%— | 0*—— | 0—— | 0r3.4—— | 0.6r4.7—— | 0r4.0*—— | |
| Other non-operating income (expense) | 31−71.7%1447% | −0.1−100%−22.6% | 26+414%3513% | 1.0−98.3%278% | 4.0*−69.4%923% | 31—8741% | 5.0+87.9%— | 60+3803%— | 13*+472%— | −22—— | 2.7r−1.5—— | 1.5r−0.5—— | 2.3r−1.7*—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Income from continuing operations | — | — | — | — | −15*—−3501% | 8.2—2337% | −20—— | 33—— | −16*—— | −51—— | −26—— | −33—— | −35*—— | |
| Income from discontinued operations | — | — | — | — | 0*—0.0% | 0−100%0.0% | 0—— | 0—— | 0*—— | 140—— | −6.7—— | −7.2—— | −6.5*—— | |
| Net income attributable to shareholders | −47−970%−2210% | −16−299%−2746% | 4.6—622% | −20−161%−5562% | −15*—−3501% | 8.2−90.8%2337% | −20—— | 33—— | −16*—— | 89—— | −33—— | −40—— | −41*—— | |
| Earnings per share, basic | — | -1.63−273%— | 0.47—— | -2.08−155%— | — | 0.94−91.9%— | -2.27—— | 3.76—— | — | 11.63r0.58—— | -4.34r-0.22—— | -5.49r-0.27—— | — | |
| Earnings per share, diluted | — | -1.63−273%— | 0.47—— | -2.08−155%— | — | 0.94−91.9%— | -2.27—— | 3.75—— | — | 11.63r0.58—— | -4.34r-0.22—— | -5.49r-0.27—— | — | |
| Shares, weighted average (basic) | 10.0+14.0%— | 10.0+14.0%— | 9.7+11.0%— | 9.6+10.1%— | — | 8.8+14.8%— | 8.7+15.4%— | 8.7+19.1%— | — | 7.6r153—— | 7.6r152—— | 7.3r146—— | — | |
| Shares, weighted average (diluted) | 10.0+13.8%— | 10.0+13.8%— | 9.7+11.5%— | 9.6+10.0%— | — | 8.8+14.9%— | 8.7+15.4%— | 8.7+19.3%— | — | 7.6r153—— | 7.6r152—— | 7.3r146—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 18—26.6% | 18−63.2%26.6% | 16−65.6%15.4% | 30−49.3%25.4% | 46+48.6%33.1% | 48−28.7%33.2% | 45−36.3%31.6% | 59−47.1%35.8% | 31−75.9%22.0% | 67—37.4% | 71—22.1% | 111—32.6% | 128—35.7% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 0.2—0.3% | 0.2−47.9%0.3% | 0.3—0.3% | 0.2—0.2% | 0.2—0.1% | 0.4—0.2% | — | — | 0—0.0% | — | — | — | — | |
| Inventory | — | — | — | — | — | — | — | — | — | — | 53—16.5% | 42—12.3% | 30—8.3% | |
| Other current assets | 4.2—6.4% | 4.2+35.3%6.4% | 1.5−38.9%1.5% | 1.8−60.4%1.5% | 3.1−46.8%2.2% | 3.1−49.0%2.2% | 2.4−62.3%1.7% | 4.5−3.0%2.7% | 5.8−27.8%4.2% | 6.1—3.4% | 6.4—2.0% | 4.6—1.3% | 8.0r9.1—2.2% | |
| Current assets | 34—52.2% | 34−33.2%52.2% | 42−13.0%41.7% | 32−51.8%27.1% | 49+27.7%35.7% | 52−29.3%35.9% | 49−67.4%33.9% | 66−60.0%40.2% | 39−78.0%27.7% | 73—40.8% | 149—46.4% | 165—48.4% | 175—48.9% | |
| Property, plant and equipment | 3.0—4.6% | 3.0−65.0%4.6% | 5.8−39.7%5.7% | 6.9−35.0%5.8% | 7.6−33.8%5.5% | 8.6−31.7%6.0% | 9.6−45.9%6.7% | 11−44.8%6.4% | 12−34.5%8.2% | 13—7.0% | 18—5.5% | 19—5.6% | 18r22—4.9% | |
| Right-of-use (leased) assets | 28—42.0% | 28−63.0%42.0% | 51−33.4%50.4% | 70−10.9%59.7% | 72−10.4%52.5% | 75−9.9%52.0% | 77−25.6%53.4% | 79−25.4%48.0% | 81−10.5%57.9% | 83—46.4% | 103—32.1% | 106—31.0% | 90r110—25.2% | |
| Total assets | 66—100% | 66−54.1%100% | 102−29.4%100% | 118−28.4%100% | 138−1.2%100% | 143−19.7%100% | 144−55.3%100% | 164−51.9%100% | 140−61.0%100% | 179—100% | 322—100% | 341—100% | 359—100% | |
| Accounts payable | 1.5—2.2% | 1.5−12.9%2.2% | 1.2−46.1%1.2% | 2.3+7.8%2.0% | 1.7−58.8%1.2% | 1.7−79.7%1.2% | 2.2−54.3%1.5% | 2.2−58.5%1.3% | 4.1+12.0%2.9% | 8.3—4.6% | 4.8—1.5% | 5.2—1.5% | 3.6—1.0% | |
| Current liabilities | 21—31.7% | 21−6.8%31.7% | 20−35.3%19.7% | 19−38.2%16.4% | 19−53.1%14.0% | 22−65.4%15.6% | 31−71.4%21.5% | 31−68.2%19.1% | 41−58.2%29.5% | 65—36.3% | 108—33.7% | 98—28.9% | 99—27.5% | |
| Lease liabilities (non-current) | 23—35.1% | 23−69.3%35.1% | 45−42.5%44.1% | 70−13.5%59.2% | 73−12.5%52.5% | 75−11.6%52.5% | 78−22.8%54.2% | 80−22.1%49.0% | 83−9.5%59.3% | 85—47.7% | 101—31.4% | 103—30.3% | 92r106—25.6% | |
| Total liabilities | 45—67.6% | 45−55.4%67.6% | 67−39.5%66.0% | 91−19.9%77.5% | 94−25.4%68.0% | 100−35.6%69.5% | 111−72.9%77.1% | 114−71.6%69.3% | 126−68.8%90.1% | 155—86.6% | 409—127% | 401—118% | 403—113% | |
| Retained earnings | −1,004—−1524% | −1,004—−1524% | −988—−972% | −992—−844% | −972—−704% | −957—−667% | −965—−671% | −945—−576% | −978—−700% | −962—−538% | −1,051—−327% | −1,018—−298% | −978—−273% | |
| Shareholders' equity | 21—32.4% | 21−51.1%32.4% | 35+4.8%34.0% | 26−47.5%22.5% | 44+221%32.0% | 44+82.7%30.5% | 33—22.9% | 50—30.7% | 14—9.9% | 24—13.4% | −87—−27.1% | −60—−17.5% | −45—−12.5% | |
| Total liabilities and equity | 66—100% | 66−54.1%100% | 102−29.4%100% | 118−28.4%100% | 138−1.2%100% | 143−19.7%100% | 144−55.3%100% | 164−51.9%100% | 140−61.0%100% | 179—100% | 322—100% | 341—100% | 359—100% | |
| Shares outstanding | 10—— | 10+14.7%— | 9.8+12.3%— | 9.6+9.9%— | 9.6r9.6+10.5%— | 8.8−94.9%— | 8.8−94.2%— | 8.7−94.2%— | 8.7r173−93.6%— | 170—— | 152—— | 151—— | 135—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.9−32.3%136% | 0.5−53.9%81.1% | 0.7−36.7%91.0% | 0.8−27.4%218% | 1.0*−12.1%218% | 1.0−25.6%297% | 1.1−25.4%— | 1.1−31.0%— | 1.1*−33.5%— | 1.4—— | 1.4—— | 1.6—— | 1.6*—— | |
| Share-based compensation | 8.6−24.9%403% | 1.9−25.1%313% | 1.7−25.7%236% | 1.8−37.4%493% | 3.2*−15.0%730% | 2.5−52.1%707% | 2.3−57.7%— | 2.8−56.6%— | 3.8*−26.0%— | 5.2—— | 5.5—— | 6.5—— | 5.1*—— | |
| Cash from operating activities | −64—−3009% | −10*−575%−1767% | −22*—−3043% | −16−161%−4570% | −15*—−3358% | 2.2*—628% | −13*—— | 27—— | −39*—— | −35*—— | −40*—— | −35—— | −47*—— | |
| Capital expenditure | −0.0—−1.4% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.0*—−6.6% | −0.0*—−2.3% | −0.2*—— | −0.0—— | −0.1*—— | −0.1*—— | −0.1*—— | −0.1—— | −0.9*—— | |
| Cash from investing activities | 13—600% | 13*—2117% | 0.0*—1.9% | 0—0.0% | 0.2*—41.3% | −0.0*−100%−2.3% | −0.2*−114%— | −0.0—— | −0.1*—— | 141*—— | 1.3*—— | −0.1—— | −0.9*—— | |
| Debt issued | — | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 16+422%732% | 0.8*+1133%127% | 1.7*—233% | 0.4−63.7%120% | 13*+629%2890% | 0.1*—17.4% | 0*—— | 1.2−93.7%— | 1.7*−73.0%— | −111*—— | 0*—— | 19—— | 6.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Seres Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Eric Shaff, Thomas DesRosier, Marella Thorell | $1.8 M | $1.4 M | $1.0 M | $13 |
| 2024Eric Shaff | $2.7 M | $1.9 M | $1.3 M | $15 |
| 2023Eric Shaff | $3.2 M | −$518 K | $1.7 M | $25 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Seres Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 3 · Agreement ended 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting noticeResults announced | 8-K | |
| Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Seres Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $117 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Associate, ManufacturingBiochemists and Biophysicists | 1 | $106 K |
| Senior Scientist, Analytical DevelopmentBiochemists and Biophysicists | 1 | $127 K |
Where: Cambridge, MA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $117 K | 2 |
| FY2025 | 4 | 4 | $108 K | 4 |
| FY2023 | 7 | 7 | $104 K | 7 |
| FY2022 | 12 | 12 | $119 K | 12 |
| FY2021 | 5 | 5 | $100 K | 5 |
| FY2020 | 1 | 1 | $115 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Seres Therapeutics, Inc.
How Seres Therapeutics, Inc. compares in Biotechnology
- Market cap$20 M · higher than 17% of 726
- Revenue$1 M · higher than 23% of 647
- P/E ratio3.5× · lower than 90% of 100
- Price / sales25.2× · lower than 27% of 339
- Price / book0.5× · lower than 93% of 534
- FCF yield4.4% · higher than 94% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Seres Therapeutics, Inc.🇺🇸 | $20 M | 3.5× | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Seres Therapeutics, Inc.? Verify and update this profile — free
Show Seres Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.